Stock 4595 MIZUHO MEDY CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Mizuho Medy Co.,Ltd.

Equities

4595

JP3885900005

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-04-26 am EDT 		5-day change 1st Jan Change
3,305 JPY -0.45% Intraday chart for Mizuho Medy Co.,Ltd. +2.01% +5.25%
2021 Mizuho Medy Co.,Ltd.(TSE:4595) added to S&P Global BMI Index CI
2020 Mizuho Medy Co.,Ltd.(TSE:4595) dropped from S&P Global BMI Index CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The company is one of the best yield companies with high dividend expectations.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • For several months, analysts have been revising their EPS estimates roughly upwards.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
MIZUHO MEDY CO.,LTD. Stock Mizuho Medy Co.,Ltd.
+5.25% 200M -
BIOMÉRIEUX Stock bioMérieux
+0.89% 12.8B
B+
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD. Stock Shenzhen New Industries Biomedical Engineering Co., Ltd.
-10.29% 7.61B
B-
DIASORIN S.P.A. Stock DiaSorin S.p.A.
+1.78% 5.41B
B
AUTOBIO DIAGNOSTICS CO., LTD. Stock Autobio Diagnostics Co., Ltd.
-1.16% 4.51B
C
LANTHEUS HOLDINGS, INC. Stock Lantheus Holdings, Inc.
+5.74% 4.49B
C
10X GENOMICS, INC. Stock 10x Genomics, Inc.
-50.70% 3.29B
D+
ANDON HEALTH CO., LTD. Stock Andon Health Co., Ltd.
+12.21% 2.73B - -
VITROLIFE AB Stock Vitrolife AB
-16.13% 2.02B
B-
GUANGZHOU WONDFO BIOTECH CO.,LTD Stock Guangzhou Wondfo Biotech Co.,Ltd
-11.50% 1.73B
D+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
-
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 4595 Stock
  4. Ratings Mizuho Medy Co.,Ltd.